The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H

Journal of Virology

Volumn 86, Issue 1, 2012, Pages 49-59

  Binka, Mawuena ^a   Ooms, Marcel ^a   Steward, Myeika ^a   Simon, Viviana ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3H; CYTIDINE DEAMINASE; UNCLASSIFIED DRUG; VIF PROTEIN;

ALLELE; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CONTROLLED STUDY; GENETIC VARIABILITY; HAPLOTYPE MAP; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPRECIPITATION; MOLECULAR RECOGNITION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

AMINO ACID SEQUENCE; AMINOHYDROLASES; CELL LINE; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; SEQUENCE ALIGNMENT; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84855982190     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06082-11     Document Type: Article

References (52)

1. Albin JS, Harris RS. 2010. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev. Mol. Med. 12:e4.
2. Bell CM, et al. 2007. Molecular characterization of the HIV type 1 subtype C accessory genes vif, vpr, and vpu. AIDS Res. Hum. Retroviruses 23: 322-330.
3. Conticello SG, Harris RS, Neuberger MS. 2003. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13:2009 -2013.
4. Cullen BR. 2006. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J. Virol. 80:1067-1076.
5. Dang Y, et al. 2008. Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J. Biol. Chem. 283:11606 -11614.
6. Dang Y, Wang X, Zhou T, York IA, Zheng YH. 2009. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. J. Virol. 83:8544-8552.
7. De Maio FA, et al. 2011. Effect of HIV-1 Vif variability on progression to pediatric AIDS and its association with APOBEC3G and CUL5 polymorphisms. Infect. Genet. Evol. 11:1256-1262.
8. Goila-Gaur R, Strebel K. 2008. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5:51.
9. Gourraud PA, et al. 2011. APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection. Hum. Immunol. 72:207-212.
10. Harari A, Ooms M, Mulder LC, Simon V. 2009. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 83:295-303.
11. Harris RS, Liddament MT. 2004. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 4:868-877.
12. Hemelaar J, Gouws E, Ghys PD, Osmanov S. 2011. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25:679-689.
13. Hultquist JF, et al. 2011. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85:11220 -11234.
14. Iwabu Y, et al. 2010. Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes. J. Biol. Chem. 285: 35350-35358.
15. Janini M, Rogers M, Birx DR, McCutchan FE. 2001. Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4[sup]+ T cells. J. Virol. 75:7973-7986.
16. Kao S, et al. 2003. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 77:11398-11407.
17. Kijak GH, et al. 2008. Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology 376:101-111.
18. Larue RS, Lengyel J, Jonsson SR, Andresdottir V, Harris RS. 2010. Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. J. Virol. 84:8193- 8201.
19. LI MM, Wu LI, Emerman M. 2010. The range of human APOBEC3H sensitivity to lentiviral Vif proteins. J. Virol. 84:88 -95.
20. Liu B, Yu X, Luo K, Yu Y, Yu XF. 2004. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J. Virol. 78:2072-2081.
21. Luo K, et al. 2005. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. U. S. A. 102:11444 -11449.
22. Marcsisin SR, et al. 2011. On the solution conformation and dynamics of the HIV-1 viral infectivity factor. J. Mol. Biol. 410:1008 -1022.
23. Mariani R, et al. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31.
24. Mehle A, et al. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279:7792-7798.
25. Mehle A, Thomas ER, Rajendran KS, Gabuzda D. 2006. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 281:17259 -17265.
26. Mehle A, et al. 2007. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J. Virol. 81:13235-13241.
27. Mulder LC, Harari A, Simon V. 2008. Cytidine deamination induced HIV-1 drug resistance. Proc. Natl. Acad. Sci. U. S. A. 105:5501-5506.
28. Mulder LC, et al. 2010. Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J. Virol. 84:9613-9617.
29. OhAinle M, Kerns JA, Li MM, Malik HS, Emerman M. 2008. Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4:249-259.
30. Ooms M, Majdak S, Seibert CW, Harari A, Simon V. 2010. The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity. J. Virol. 84:7961-7969.
31. Paul I, Cui J, Maynard EL. 2006. Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc. Natl. Acad. Sci. U. S. A. 103: 18475-18480.
32. Pery E, Rajendran KS, Brazier AJ, Gabuzda D. 2009. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 83:2374 -2381.
33. Piantadosi A, Humes D, Chohan B, McClelland RS, Overbaugh J. 2009. Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. J. Virol. 83:7805-7814.
34. Russell RA, Pathak VK. 2009. Identification of Two Distinct HIV-1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 83:1992-2003.
35. Schrofelbauer B, Senger T, Manning G, Landau NR. 2006. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 80: 5984-5991.
36. Simon JH, Sheehy AM, Carpenter EA, Fouchier RA, Malim MH. 1999. Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J. Virol. 73:2675-2681.
37. Simon V, et al. 2005. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1:e6.
38. Smith JL, Bu W, Burdick RC, Pathak VK. 2009. Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends Pharmacol. Sci. 30:638-646.
39. Stanley BJ, et al. 2008. Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J. Virol. 82:8656-8663.
40. Stephens EB, Singh DK, Pacyniak E, McCormick C. 2001. Comparison of Vif sequences from diverse geographical isolates of HIV type 1 and SIV(cpz) identifies substitutions common to subtypeCisolates and extensive variation in a proposed nuclear transport inhibition signal. AIDS Res. Hum. Retroviruses 17:169 -177.
41. Tan L, Sarkis PT, Wang T, Tian C, Yu XF. 2009. Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J. 23:279 -287.
42. Tian C, et al. 2006. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 80:3112-3115.
43. Wang X, et al. 2011. Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J. Virol. 85: 3142-3152.
44. Wichroski MJ, Ichiyama K, Rana TM. 2005. Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. J. Biol. Chem. 280:8387- 8396.
45. Wieland U, et al. 1994. In vivo genetic variability of the HIV-1 vif gene. Virology 203:43-51.
46. Wieland U, et al. 1997. Diversity of the vif gene of human immunodeficiency virus type 1 in Uganda. J. Gen. Virol. 78:393- 400.
47. Xiao Z, Ehrlich E, Luo K, Xiong Y, Yu XF. 2007. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 21:217-222.
48. Xiao Z, et al. 2007. Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J. Mol. Biol. 373:541-550.
49. Yamashita T, Doi N, Adachi A, Nomaguchi M. 2008. Growth ability in simian cells of monkey cell-tropic HIV-1 is greatly affected by downstream region of the vif gene. J. Med. Invest. 55:236 -240.
50. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. 2004. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18: 2867-2872.
51. Zennou V, Perez-Caballero D, Gottlinger H, Bieniasz PD. 2004. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol. 78:12058 -12061.
52. Zhen A, Wang T, Zhao K, Xiong Y, Yu XF. 2010. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J. Virol. 84:1902-1911.